Please login to the form below

Not currently logged in
Email:
Password:

Tivicay

This page shows the latest Tivicay news and features for those working in and with pharma, biotech and healthcare.

ViiV’s two-drug HIV combo backed by CHMP

ViiV’s two-drug HIV combo backed by CHMP

The advisory committee issued a positive opinion for Juluca - which combines ViiV’s integrase inhibitor Tivicay (dolutegravir) with a non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine) developed by Johnson &Johnson’s

Latest news

  • Gilead’s triple HIV drug approval prompts GSK lawsuit Gilead’s triple HIV drug approval prompts GSK lawsuit

    The lawsuit has been submitted in the US and Canada and is seeking to prove that bictegravir infringes on intellectual property held by ViiV for its rival integrase inhibitor Tivicay (dolutegravir), ... forecasts. Tivicay and Triumeq posted strong growth

  • GSK’s ViiV gets US okay for two-drug HIV regimen GSK’s ViiV gets US okay for two-drug HIV regimen

    GSK’ s ViiV gets US okay for two-drug HIV regimen. Juluca is a combination of ViiV’s Tivicay and Janssen’s Edurant. ... Descovy was approved in the US last year and is often prescribed alongside Tivicay.

  • CDC backs GSK’s Shingrix over Merck & Co’s Zostavax CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

    Once again HIV therapies Tivicay (dolutegravir) and Triumeq (dolutegravir, abacavir and lamivudine) - up 45% to £1.47bn - led the advance amongst GSK’s prescription pharma business, with support from new asthma

  • ViiV files two-drug HIV maintenance regimen ViiV files two-drug HIV maintenance regimen

    The company - majority-owned by GlaxoSmithKline - has filed for approval of a single tablet formulation containing integrase inhibitor Tivicay (dolutegravir) and the active ingredient in Janssen's non-nucleoside reverse transcriptase

  • Gilead plans fightback against HIV arch-rival ViiV Gilead plans fightback against HIV arch-rival ViiV

    Triumeq, which contains rival integrase Tivicay (dolutegravir) as well as abacavir and lamivudine. ... The new data represents an opportunity for Gilead to stage a comeback in the HIV category, where it has been losing market share to ViiV due to the

More from news
Approximately 8 fully matching, plus 24 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Developing your patient-centric strategy

    The 2013 PatientView survey likely scored ViiV well on the product front too, as 2013 saw the company’ s HIV therapy Tivicay (dolutegravir) approved in the US and recommended for European

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics